Waters - WAT Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Waters in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WAT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WAT, but not buy additional shares or sell existing shares.
View WAT analyst ratings or view top-rated stocks.

6 brokers have issued 12-month target prices for Waters' stock. Their WAT share price forecasts range from $315.00 to $378.00. On average, they expect the company's share price to reach $348.25 in the next twelve months. This suggests a possible upside of 29.2% from the stock's current price.
View analysts price targets for WAT or view top-rated stocks among Wall Street analysts.

Waters' stock was trading at $372.60 at the beginning of the year. Since then, WAT stock has decreased by 27.7% and is now trading at $269.53.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our WAT earnings forecast.

Waters Co. (NYSE:WAT) posted its quarterly earnings results on Tuesday, August, 2nd. The medical instruments supplier reported $2.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.12. The medical instruments supplier had revenue of $714.30 million for the quarter, compared to analyst estimates of $706.77 million. Waters had a trailing twelve-month return on equity of 203.31% and a net margin of 24.21%. Waters's revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.60 EPS.
Read the conference call transcript.

Waters issued an update on its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of $2.50-$2.60 for the period, compared to the consensus earnings per share estimate of $2.70. The company issued revenue guidance of $672.42 million-$685.60 million, compared to the consensus revenue estimate of $683.37 million.

13 employees have rated Waters Chief Executive Officer Udit Batra on Glassdoor.com. Udit Batra has an approval rating of 100% among the company's employees. This puts Udit Batra in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Waters investors own include Thermo Fisher Scientific (TMO), Raytheon Technologies (RTX), CVS Health (CVS), Home Depot (HD), Johnson & Johnson (JNJ), Abbott Laboratories (ABT), Verizon Communications (VZ), Cisco Systems (CSCO) and Walmart (WMT).

Waters trades on the New York Stock Exchange (NYSE) under the ticker symbol "WAT."

Shares of WAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of WAT stock can currently be purchased for approximately $269.53.

Waters (NYSE:WAT) has a market capitalization of $16.14 billion and generates $2.79 billion in revenue each year. The medical instruments supplier earns $692.84 million in net income (profit) each year or $11.46 on an earnings per share basis.

The company employs 7,800 workers across the globe.

Waters' mailing address is 34 MAPLE STREET, MILFORD MA, 01757. The official website for the company is www.waters.com. The medical instruments supplier can be reached via phone at (508) 478-2000, via email at investor_relations@waters.com, or via fax at 508-872-1990.